SANTEN PHARMACEUTICAL CO., LTD.
4536・Prime Market・Pharmaceuticals
Governance
As a company with a Board of Corporate Auditors, the company has six directors (three of whom are outside directors) and four corporate auditors (three of whom are outside corporate auditors), with outside officers constituting a majority on both the Board of Directors and the Board of Corporate Auditors. Three voluntary committees—the Nomination Committee, the Executive Compensation Committee, and the Strategy Deliberation Committee—have been established to ensure transparency and objectivity in management.
Risk Management
The Company has established a Crisis Management Committee chaired by the Representative Director, President and CEO, building a structure in which the risk management department coordinates with subsidiaries to identify, assess, and respond to risks across the entire group. The Internal Audit Office, reporting directly to the President, conducts internal audits of the risk management status from an independent standpoint, and risks and opportunities related to the 13 materiality issues are regularly assessed and reported through the Sustainability Committee.
Shareholder Returns
Progressive dividend policy is the basic approach, with the current level (¥19 per half-year) set as the floor. For FY2026 (ending March 2026), the annual dividend is planned at ¥38 (interim ¥19, year-end ¥19), with a payout ratio of 33.3%. For FY2027 (ending March 2027), the dividend is planned to increase to ¥42 annually (interim ¥21, year-end ¥21). Share buybacks are also conducted flexibly (¥32,797 million repurchased during the fiscal year).
Dividend Policy
The company will continue a progressive dividend policy, setting the current level (¥19 per half-year) as the floor, and will provide direct returns to shareholders through dividend increases accompanying profit growth, combined with flexible share buybacks. FY2026 (ending March 2026) results: interim ¥19, year-end ¥19, annual ¥38 (total dividends ¥12,285 million, payout ratio 33.3%, dividend on equity attributable to owners of the parent 4.3%). FY2027 (ending March 2027) forecast: interim ¥21, year-end ¥21, annual ¥42 (payout ratio forecast 34%).
ESG
Santen has identified 13 materiality issues, positioning contribution to eye health, product quality, and human capital strengthening as its most critical priorities. In its climate change response, under SBT approval, the company has set a target of reducing Scope 1 and 2 CO2 emissions by 50% by 2030 compared to FY2019 levels; FY2024 results showed a 1.9% reduction versus the base year (34,870 tons-CO2). In terms of human capital, the company achieved a female manager ratio of 18.7% (Japan) and a global engagement score of 73%.
Last updated: June 18, 2026